Radicava slows ALS
BCLI 'hopefully' slows/stops/reverses ALS. If its all 3, then we should steamroll Radicava.
IF C$120 is negotiated by 50%, C$60K adjusted to US$45K, x50,000 US patients $2.2B, more conservative 25,000 patients, $1.1B, assume 20% net profit, $200M+ across 30M share count = $6+ EPS. If ROW is equal in size but smaller profitability, assume half EPS or $3/share. Total $9 EPS, conservatively...that is without other business being pursued in MS, ALZ, COVID. Biggest questions obviously are what the insurance determination is and how many countries in the world would fund treatments.. ie net net what BCLI profitability is. Until that is determined, it will be hard to nail this down.
If Canada is a role model, and we achieve 20% net, at 15x EPS, this is conservatively $150 over the next 2-3 years...perhaps sooner?
Chaim has a rocket ship on the pad, being loaded with fuel. It only maximum 6 months before lift-off.
News 
Market Data 
Discover 
